Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2023-08-19 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please refer to attached details w.r.t., loss of share certificate.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the loss of share certificates by a shareholder and the subsequent request for issuance of duplicate share certificates. It references regulatory compliance under SEBI regulations and circulars. The content is an official notification about a specific event related to share certificates, not a financial report, earnings release, or management discussion. It does not contain financial data or results, nor is it a report publication announcement. The document fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit other specific categories.
2023-08-19 English
Restructuring
Capital/Financing Update Classification · 95% confidence The document is an official announcement dated August 14, 2023, from Morepen Laboratories Limited addressed to stock exchanges (BSE and NSE) under Regulation 30 of the SEBI Listing Regulations. It details the outcome of a Board Meeting where the Board approved the transfer of the Formulation Distribution & Marketing Business to a wholly owned subsidiary via a slump sale. The document includes an annexure with detailed disclosures about the transaction, financial figures, rationale, and compliance with regulatory requirements. There are no financial statements or comprehensive financial performance data presented; rather, it is a regulatory disclosure about a corporate action approved by the Board. This fits the category of a Capital/Financing Update (CAP) as it relates to a significant restructuring transaction affecting the company's business segments and capital structure through a slump sale to a subsidiary. The document is not a full financial report, earnings release, or management discussion, nor is it a simple announcement of a report publication. Therefore, the appropriate classification is CAP with high confidence.
2023-08-14 English
Disclosure under Regulation 30 of SEBI(LODR) Regulations, 2015
Capital/Financing Update Classification · 95% confidence The document is an official announcement dated August 14, 2023, from Morepen Laboratories Limited addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. The key content is the approval of the transfer of the Formulation Distribution & Marketing Business to a wholly owned subsidiary via a slump sale. The document includes detailed disclosures pursuant to Regulation 30 of the SEBI Listing Regulations, which governs material events and disclosures by listed companies in India. The document provides financial details, rationale, and procedural information about the transaction but does not contain financial statements or detailed financial analysis. It is a regulatory announcement about a corporate action (business transfer) approved by the Board, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the transaction itself. The document fits best under Capital/Financing Update (CAP) as it relates to a significant restructuring of the company's business and capital structure through a slump sale to a subsidiary, which affects the company's operations and financial consolidation.
2023-08-14 English
Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform that, the Board of Directors of the company in their meeting held Monday i.e., August 14, 2023 (commenced at ....
Capital/Financing Update Classification · 95% confidence The document is an official announcement dated August 14, 2023, from Morepen Laboratories Limited addressed to stock exchanges (BSE and NSE) under Regulation 30 of the SEBI Listing Regulations. It details the outcome of a Board Meeting where the Board approved the transfer of the Formulation Distribution & Marketing Business to a wholly owned subsidiary via a slump sale. The document includes an annexure with detailed disclosures about the transaction, financial figures, rationale, and compliance with regulatory requirements. The content is focused on a corporate action related to business restructuring and transfer of assets rather than financial results, management changes, or other report types. It is not a full financial report, earnings release, or management discussion but a regulatory announcement about a significant corporate transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to changes in the company's capital structure and business operations through a slump sale to a subsidiary.
2023-08-14 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is an official announcement dated August 14, 2023, from Morepen Laboratories Limited addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. The subject is the approval of the transfer of the Formulation Distribution & Marketing Business to a wholly owned subsidiary via a slump sale. The document references compliance with SEBI Listing Regulations and provides detailed disclosure information pursuant to Regulation 30 of SEBI Listing Regulations, including financial details, rationale, and transaction specifics. There is no indication of this being a full financial report, audit report, or earnings release. It is a regulatory announcement about a corporate action approved by the board. The document is not a report itself but an announcement of a board decision and related disclosures. Therefore, the classification best fitting this document is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit other specific categories like M&A filings or capital changes, since it is about a business transfer within the group but not a merger or acquisition in the strict sense, nor a capital change or share issue. Confidence is high given the clear regulatory references and the nature of the content.
2023-08-14 English
Loss of Share Certificates
Regulatory Filings
2023-08-09 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.